Umecrine Cognition signs partnering agreement with CleveXel Pharma

STOCKHOLM – October 23, 2013. Umecrine Cognition AB, a Karolinska Development portfolio company, today announced that the company has entered into a partnering agreement with CleveXel Pharma regarding the development of its lead program in hepatic encephalopathy.According to the agreement, CleveXel Pharma will co-fund the development of Umecrine Cognition’s lead program in hepatic encephalopathy through investments in shares in the company. Umecrine Cognition will use the proceeds for payments for services that CleveXel provides for the preclinical and clinical development through to proof-